Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18343707 | 0.89 | KDM4E (0.46) | KDM4EPOLBALDH1A1HPGDCYP1A2 | |
| SCHEMBL4759902 | 0.84 | SMN1; SMN2 (0.52) | KDM4EPOLBALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL29302837 | 0.83 | KDM4E (0.45) | KDM4EPOLBALDH1A1HPGDCYP1A2 | |
| SCHEMBL25973905 | 0.82 | KDM4E (0.51) | KDM4EPOLBALDH1A1HPGDCYP1A2 | |
| SCHEMBL31189896 | 0.82 | PLAT (0.43) | KDM4EPOLBALDH1A1HPGDCYP1A2 | |
| SCHEMBL25973792 | 0.81 | KDM4E (0.62) | KDM4EPOLBALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL21177423 | 0.81 | KDM4E (0.45) | KDM4EPOLBALDH1A1HPGDCYP1A2 | |
| SCHEMBL31001796 | 0.81 | KDM4E (0.48) | KDM4EPOLBALDH1A1HPGDCYP1A2 | |
| SCHEMBL24695811 | 0.80 | HPGD (0.42) | KDM4EPOLBALDH1A1HPGDCYP1A2 | |
| SCHEMBL24695991 | 0.80 | HPGD (0.42) | KDM4EPOLBALDH1A1HPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486274-B2 | Substituted pyrazolo-pyrimidines and uses thereof | Verge Analytics, Inc. (US) | 2025-12-02 | — | — | US | disclosed |
| CN-115209952-B | Substituted pyrazolopyrimidines and use thereof | 维基分析有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-12215112-B2 | CD151 inhibitors | Esfam Biotech Pty Ltd (AU) | 2025-02-04 | — | — | US | disclosed |
| WO-2024254599-A1 | HPGD INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| EP-4469454-A1 | PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE | Janssen Pharmaceutica NV (BE) | 2024-12-04 | — | — | EP | disclosed |
| US-20230365567-A1 | COMPOUNDS | Esfam Biotech Pty Ltd (AU) | 2023-11-16 | — | — | US | disclosed |
| US-20230365567-A1 | COMPOUNDS | Esfam Biotech Pty Ltd (AU) | 2023-11-16 | — | — | US | disclosed |
| US-20230365567-A1 | COMPOUNDS | Esfam Biotech Pty Ltd (AU) | 2023-11-16 | — | — | US | disclosed |
| EP-3760631-B1 | CRYSTAL SALT OF PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2023-11-08 | — | — | EP | disclosed |
| EP-3760631-B1 | CRYSTAL SALT OF PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2023-11-08 | — | — | EP | disclosed |
| US-10227349-B2 | Pyrazolo[1,5-a]pyrimidine compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-03-12 | — | — | US | disclosed |
| WO-2018043461-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUND | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2018-03-08 | — | — | WO | disclosed |
| US-20180057499-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-03-01 | — | — | US | disclosed |
| US-20180057499-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-03-01 | — | — | US | disclosed |
| US-20180057499-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-03-01 | — | — | US | disclosed |
| EP-2539342-B1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-04-15 | — | — | EP | disclosed |
| US-8969376-B2 | Pyrazolopyrimidine compounds and their use as PDE10 inhibitors | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-03-03 | — | — | US | disclosed |
| EP-2539342-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-20120309754-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-12-06 | — | — | US | disclosed |
| WO-2011105628-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486274-B2 | Substituted pyrazolo-pyrimidines and uses thereof | PIKFYVE, PIP4K2B, PIP4K2C | KDM4E 1122/4885POLB 787/4885ALDH1A1 4827/4885 |
| US-10227349-B2 | Pyrazolo[1,5-a]pyrimidine compound | F2RL1, F2R, F2RL3 | KDM4E 3791/4885POLB 3092/4885ALDH1A1 2871/4885 |
| US-20230365567-A1 | COMPOUNDS | CD81, CD47, CD59 | KDM4E 3277/4885POLB 4713/4885ALDH1A1 128/4885 |
| US-12215112-B2 | CD151 inhibitors | CD81, CD47, CD4 | KDM4E 2702/4885POLB 4720/4885ALDH1A1 601/4885 |
| US-20180057499-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUND | DPYD, XDH, XPO5 | KDM4E 3864/4885POLB 383/4885ALDH1A1 1032/4885 |
| US-20120309754-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PDE3B, PDE3A, PDE5A | KDM4E 408/4885POLB 1131/4885ALDH1A1 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.